Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells

US10874753B2 · kind B2 · utility

Assignees

• The South African Nuclear Energy Corporation Limited · ZA
• UNIVERSITY OF CAPE TOWN · ZA

Inventors

• Cathryn Helena Stanford Driver · Modimolle, ZA
• Jan Rijn Zeevaart · Pretoria, ZA
• Mohamed Iqbal Parker · Cape Town, ZA
• Roger Hunter · Bakersfield, US

Key dates

• Filing date: Sep 25, 2015
• Grant date: Dec 29, 2020
• Expiry date: Mar 13, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K51/121
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.